Fintel reports that on April 9, 2025, Goldman Sachs upgraded their outlook for Johnson & Johnson (NYSE:JNJ) from Neutral to ...

Fintel reports that on April 10, 2025, Goldman Sachs downgraded their outlook for Visteon (NasdaqGS:VC) from Buy to Neutral. Analyst Price Forecast Suggests 48.98% Upside As of April 2, 2025, the ...

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p15,318.00.

Goldman Sachs analyst Gurpreet Singh maintained a Buy rating on HSBC Holdings (HSBA – Research Report) today and set a price target of £10.05.

Three of the largest banks in the US say one of the year's best performing assets still has more room to run to the upside.

U.S. investment bank Goldman Sachs lowered its forecasts for China's GDP growth to 4% in 2025 and 3.5% in 2026 in a report ...

Stocks are melting down across the globe, and US market leadership is in jeopardy. But clients of Goldman Sachs Asset ...

The U.S. Department of Defense for around 17% of Palantir's overall revenue in 2024, and around 18% in 2023, according to its annual report ... of AI demand. Goldman Sachs analyst Gabriela ...

Goldman Sachs is catching fresh heat over massive bonuses it has pledged to CEO David Solomon and his No. 2 executive John Waldron — with powerful shareholder voting advisors slamming the ...

According to the annual report, Goldman Sachs has around $748 billion in total ... as their listed brothers. Analyst’s Disclosure: I/we have a beneficial long position in the shares of 38144QAA7 ...